Aryl substituted pyrimidines

Details Aryl substituted pyrimidines Aryl substituted pyrimidines

2005-03-15

2005-03-15

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S298000, C544S315000, C544S316000, C544S317000, C544S319000, C544S204000, C544S213000, C544S217000, C544S218000, C544S336000, C544S408000, C514S241000, C514S252100, C514S277000, C546S290000, C546S296000, C546S297000

Reexamination Certificate

active

06867210

ABSTRACT:
This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I:or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein A1, A2, A3, R1-R4, X and Y are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

REFERENCES:
patent: 3149109 (1964-09-01), Rorig et al.
patent: 3502673 (1970-03-01), Hepworth et al.
patent: 3631036 (1971-12-01), Kim et al.
patent: 3660414 (1972-05-01), Hardtmann et al.
patent: 3709888 (1973-01-01), Hardtmann et al.
patent: 3886167 (1975-05-01), Ash et al.
patent: 3940404 (1976-02-01), Ash et al.
patent: 4133956 (1979-01-01), Abdulla et al.
patent: 4293552 (1981-10-01), Miesel
patent: 4332809 (1982-06-01), Honma et al.
patent: 4364956 (1982-12-01), Clark et al.
patent: 4530842 (1985-07-01), Bormann
patent: 4698091 (1987-10-01), Brunner et al.
patent: 4701208 (1987-10-01), Los
patent: 4912218 (1990-03-01), Coyle et al.
patent: 4920119 (1990-04-01), Attwood et al.
patent: 4968702 (1990-11-01), Poletto et al.
patent: 5084462 (1992-01-01), Ackerman et al.
patent: 5116989 (1992-05-01), Hale et al.
patent: 5250533 (1993-10-01), Heinemann et al.
patent: 5340701 (1994-08-01), Desobry
patent: 5389632 (1995-02-01), Bru-Magniez et al.
patent: 5403934 (1995-04-01), Batchelor et al.
patent: 5405553 (1995-04-01), Terada et al.
patent: 5602156 (1997-02-01), Kohn et al.
patent: 5744492 (1998-04-01), Kohn et al.
patent: 6057346 (2000-05-01), Kohn et al.
patent: 6127371 (2000-10-01), Elliott et al.
patent: 30 12 597 (1980-10-01), None
patent: 32 39 573 (1983-05-01), None
patent: 32 45 950 (1983-07-01), None
patent: 0 096 657 (1983-12-01), None
patent: 0 123 700 (1984-11-01), None
patent: 0 200 024 (1986-11-01), None
patent: 0 271 195 (1988-06-01), None
patent: 0 362 578 (1990-04-01), None
patent: 0 389 236 (1990-09-01), None
patent: 0 389 236 (1991-02-01), None
patent: 0 428 268 (1991-05-01), None
patent: 0 446 604 (1991-09-01), None
patent: 0 446 604 (1992-02-01), None
patent: 0 480 258 (1992-04-01), None
patent: 0 480 258 (1992-09-01), None
patent: 0 507 962 (1992-10-01), None
patent: 0 518 798 (1992-12-01), None
patent: 0 550 900 (1993-07-01), None
patent: 0 518 798 (1994-12-01), None
patent: 0 706 795 (1996-04-01), None
patent: 1 052 238 (2000-11-01), None
patent: 1477021 (1967-04-01), None
patent: 1536093 (1967-09-01), None
patent: 2 095 240 (1982-09-01), None
patent: 2 095 240 (1982-09-01), None
patent: 56104883 (1981-08-01), None
patent: 6320234 (1988-04-01), None
patent: 02052360 (1990-02-01), None
patent: 7076542 (1995-03-01), None
patent: WO 9206085 (1992-04-01), None
patent: WO 9519358 (1995-07-01), None
patent: WO 9640628 (1996-12-01), None
patent: WO 9837068 (1998-08-01), None
patent: WO 9847869 (1998-10-01), None
patent: WO 9931062 (1999-06-01), None
patent: WO 9931088 (1999-06-01), None
patent: WO 9932468 (1999-07-01), None
patent: WO 9938829 (1999-08-01), None
patent: WO 0057877 (2000-10-01), None
El-Kafrawy et al. J. Chem. Soc. Pak. 14(1) 59-66, 1992.*
Gómez-Parra, V., et a., “New Cardiotonic Agents Related to Amrinone: Synthesis of 1,2-Dihydro-5-arylpyridin-2-ones,”Arch. Pharm(Weinheim)325:483-490, VCH Verlagsgesellschaft mbH (1992).
Dialog File 351, Accession No. 3689403, Derwent WPI English language abstract for German Patent Publication No. DE 32 39 573 A1 (Document A07), Derwent Information Ltd. (1983).
Dialog File 351, Accession No. 12589045, Derwent WPI English language abstract for WIPO Publication No. WO 99/31062 A1 (Document AN8), Derwent Information Ltd. (1999).
Dialog File 351, Accession No. 4789463, Derwent WPI English language abstract for European Patent No. EP 0 200 024 B1 (Document AN7).
Chen, C., et al., “A Convenient Synthetic Method for Trisubstituted s-Triazines,”J. Org. Chem. 60:8428-8430, The American Chemical Society (1995).
Honma, Y., et al., “Antiallergic Agents. 2. N-(1H-Tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides,”J. Med. Chem. 26:1499-1504, The American Chemical Society (1983).
Matsumoto, I., “N-Tetrazol-5-yl-6-phenyl-2-pyridinecarboxamides,” Chem. Abstr. 96:181290v, The American Chemical Society (1982).
International Search Report for International Patent Application No. PCT/US01/07797, mailed Oct. 9, 2001.
Akopian, A.N., et al., “the tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways,”Nat. Neurosci. 2:541-548, Nature America Inc. (Jun. 1999).
Backonja, M., et al., “Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus,”J. Am. Med. Assoc. 280:1831-1836, American Medical Association (1998).
Baker, M.D. and Wood, J.N., “Involvement of Na+channels in pain pathways,”Trends Pharm. Sci. 22:27-31, Elsevier Science Ltd. (Jan. 2001).
Bennett, G.J., “Neuropathic Pain: New Insights, New Interventions,”Hosp. Prac. 33:95-98, 101-104, 107-110, 113-114, The McGraw-Hill Companies (1998).
Bowsher, D., “Neurogenic pain syndromes and their management,”Br. Med. Bull. 47:644-666, Oxford University Press (1991).
Carver, A.C. and Foley, K.M., “Palliative Care,” in:Cancer Medicine, Holland, J.F., et al., eds., Williams & Wilkins, Baltimore, Maryland, pp. 992-1000 (1997).
Carver, A.C. and Foley, K.M., “Complications of Cancer and Its Treatment, Management of Cancer Pain,” in:Cancer Medicine, Holland, J.F., et al., eds., Williams & Wilkins, Baltimore, Maryland, pp. 2204-2223 (1997).
Cavallini, G., et al., “Chemioterapici Antivirali, Nota X—Mono e bis aldeidi aromatiche,” Il Farmaco Ed. Sc. 19:964-971, Il Farmaco (1964).
Cavallini, G., et al., “Antiviral Compounds. X. Aromatic mono-and dialdehydes,”Chem. Abstracts 62:Abstract No. 5217h, The American Chemical Society (1965).
Chadda, V.S. and Mathur, M.S., “Double Blind Study of the Effects of Diphenylhydantoin Sodium on Diabetic Neuropathy,”Jr. Asso. Phys. Ind. 26:403-406, Association of Physician of India (1978).
Clark, M. and Post, R.M., “Carbamazepine, but not caffeine, is highly selective for adenosine A1binding sites,”Eur. J. Pharmacol. 164:399-401, Elsevier Science Publishers B.V. (1989).
Collins, S.L., et al., “Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic Neuralgia: A Quantitative Systematic Review,”J. Pain Symptom Management 20:449-458, Elsevier (Dec. 2000).
Coward, K., et al., “Plasticity of TTX-sensitive sodium channels PN1 and Brain III in injured human nerves,”Neuroreport 12:495-500, Lippincott Williams & Wilkins (Mar. 2001).
D'Agostino, V.F., et al., “Absorption Spectra of Tetracyclones. V,”J. Org. Chem. 23:1539-1544, The American Chemical Society (1958).
Dreixler, J.C., et al., “Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds,”Eur. J. Pharmacol. 401:1-7, Elsevier Science B.V. (Jul. 2000).
England, J.D., et al., “Sodium channel accumulation in humans with painful neuromas,”Neurology 47:272-276, Lippincott-Raven (1996).
Foley, K.M., “Supportive Care and Quality of Life, Management of Cancer Pain,” in:Cancer: Principles&Practice of Oncology, Fifth Edition, DeVita Jr., V.T., et al., eds. Lippincott-Raven Publishers, Philadelphia, Pennsylvania, pp. 2807-2841 (1997).
Foley, K.M., “Supportive Care and Quality of Life, Management of Cancer Pain,” in:Cancer: Principles&Practice of Oncology, Sixth Edition, DeVita Jr., V.T., et al., eds. Lippincott-Williams & Wilkins Publisher

Affiliated with

Also associated with

Rating

Aryl substituted pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl substituted pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl substituted pyrimidines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3413649